Many of the currently available alternative hormonal therapies, that can be used after tamoxifen may have limitations in terms of tolerability and convenience. Where do you turn after tamoxifen? 'Arimidex' may offer you and your patients an alternative, new hope.

New from Zeneca Pharma, the oncology company which researched and developed tamoxifen, 'Arimidex' is the first once daily, oral, highly selective, non-steroidal aromatase inhibitor for advanced, post-menopausal breast cancer.

'Arimidex' has been shown in trials to produce a clinical benefit in over a third of patients and to be as clinically effective as megestrol acetate, but was associated with significantly fewer patients complaining of weight gain - and significantly fewer patients on 'Arimidex' experienced a weight gain of >10% (compared to entry).

Also, as 'Arimidex' is a highly selective, non-steroidal aromatase inhibitor, there is no need for concomitant steroid replacement therapy.

And once a day convenience facilitates good patient compliance.

So when the time comes to move on from tamoxifen, because life is worth living, consider 'Arimidex'.

'Arimidex' is a trade mark, the property of Zeneca Limited
Reference: 1. Data on file
Further information is available from:
Zeneca Pharma
King's Court
Water Lane
Wilmslow
Cheshire SK9 5AZ